Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

FDA Unapproved Drug Draft Compliance Policy Allows One-Year Grace Period

Oct 27 2003

• By The Tan Sheet

Related Content

Rx Extended-Release Guaifenesin Must Exit Market By November, FDA Says

Mar 03 2003

FDA Guaifenesin Crackdown Based On Adams Labs NDA “Improper” – Petition

Nov 18 2002

Adams Mucinex Approval Spurs FDA Crackdown On Guaifenesin Products

Oct 21 2002

Additional Topics

OTC Drugs Consumer

More from Archive

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window